Oncology Clinical Trials in New Brunswick, NJ
As of September 2026, 112 paid clinical trials are recruiting for Oncology in New Brunswick, New Jersey. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in New Brunswick
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
113 clinical trials for Oncology
·Clear filters·Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Top Research Study Locations in New Brunswick
Researchers run research studies in New Brunswick, NJ at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Rutgers Cancer Institute of New Jersey | Breast Cancer, Acute Myeloid Leukemia, Multiple Myeloma | 111 |
| Rutgers Cancer Institute | Bladder Cancer, Breast Cancer, Cancer | 36 |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | B Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ganglioneuroblastoma, Nodular | 22 |
| Saint Peter's University Hospital | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Acute Lymphoblastic Leukemia | 20 |
| Rutgers Robert Wood Johnson Medical School | Opioid Use, Acute Otitis Media, Aortic Stenosis, Calcific | 19 |
| Robert Wood Johnson University Hospital | Aortic Valve Insufficiency, Aortic Valve Stenosis, AMI | 17 |
| Robert Wood Johnson Medical School | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 9 |
| Rutgers University | Advanced Breast Cancer, Aneurysm, Brain, Anxiety | 9 |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | Cervical Cancer, Anal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 6 |
| Rutgers Cancer Institute of New Jersey | Breast Cancer, Breast Neoplasms, Malignant Neoplasm | 6 |
| Rutgers | Advanced Urothelial Cancer, Aortoiliac Occlusive Disease, Breast Neoplasms | 5 |
| Rutgers - Robert Wood Johnson Medical School | Cystic Fibrosis, Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation | 4 |
| Cancer Institute of New Jersey | Anxiety, Caregiver Stress Syndrome, Metastases, Neoplasm | 4 |
| GSK Investigational Site | Asthma, Neoplasms, Scleroderma, Systemic | 3 |
| Rutgers, The State University of New Jersey | Cervical Cancer, Coagulation Disorder, Papilloma Viral Infection | 3 |
| Saint Peter's University Hospital - New Brunswick | Cerebroside Lipidosis Syndrome, Fabry Disease, Gaucher Disease | 3 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC), Non-Small Cell Lung Cancer | 2 |
| Clinical Trial Site | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Transthyretin Amyloidosis With Cardiomyopathy | 2 |
| Institute for Food, Nutrition, and Health | Type 2 Diabetes, Brain Blood Flow, Cognition | 2 |
| Jack & Sheryl Morris Cancer Center | Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma, Sickle Cell Disease | 2 |
| Robert Wood Johnson University Hospital Clinical Research Center | Type 2 Diabetes, Brain Blood Flow, Cognition | 2 |
| Rutgers Cancer Institute of NJ | Advanced Solid Malignancies, Endometrial Adenocarcinoma | 2 |
| Rutgers Health | Pancreatic Cystic Lesions, Triple Negative Breast Cancer | 2 |
| Rutgers University (Data Collection Only) | Hepatectomy, Malignant Mesothelioma, Malignant Peritoneal Mesothelioma | 2 |
| Rutgers University Loree Gymnasium | Type 2 Diabetes, Brain Blood Flow, Cognition | 2 |
Active & Upcoming Studies in New Brunswick (2026)
Recruiting trials in New Brunswick grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (175 active studies)
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) · Phase 3 · Bristol-Myers Squibb
- Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents · Rutgers, The State University of New Jersey
Diabetes & metabolic (12 active studies)
- Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study · Endogenex, Inc.
- Exercise and Intranasal Insulin in Type 2 Diabetes · Phase 2, Phase 3 · Rutgers, The State University of New Jersey
Cardiovascular (12 active studies)
- Remote Patient Monitoring for Chronic Hypertension During Pregnancy (REACH) · Rutgers, The State University of New Jersey
- Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · Rutgers, The State University of New Jersey
Neurology & pain (11 active studies)
- FROST-STERN Trial: A Trial of Intraoperative Cryoablation for Post Operative Pain Management After Full Sternotomy · Rutgers, The State University of New Jersey
- Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors · Rutgers, The State University of New Jersey
Mental health & behavior (8 active studies)
- Cigarette Filter Study · Rutgers, The State University of New Jersey
- Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · Rutgers, The State University of New Jersey
Vaccines (1 active study)
Pediatric (1 active study)
- Digital Self-Management and Peer Mentoring Intervention · Rutgers, The State University of New Jersey
Common conditions studied in New Brunswick
- Breast Cancer (14 active studies)
- Acute Myeloid Leukemia (10 active studies)
- Cancer (8 active studies)
- Breast Neoplasms (7 active studies)
- Bladder Cancer (5 active studies)
- Malignant Neoplasm (5 active studies)
Leading research sponsors in New Brunswick
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in New Brunswick?
There are approximately 336 recruiting clinical trials in New Brunswick, New Jersey listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Brunswick pay participants?
Most recruiting trials in New Brunswick compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Brunswick?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Brunswick?
The most common conditions under active study in New Brunswick include Breast Cancer (14), Acute Myeloid Leukemia (10), Cancer (8), Breast Neoplasms (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Brunswick?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Brunswick on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Brunswick?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Brunswick?
Recruiting research sites in New Brunswick include Rutgers Cancer Institute of New Jersey, Rutgers Cancer Institute, Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Brunswick right now?
The largest active categories in New Brunswick are Cancer & tumors (175), Diabetes & metabolic (12), Cardiovascular (12). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.